228 related articles for article (PubMed ID: 11207029)
1. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population.
Loriot MA; Rebuissou S; Oscarson M; Cenée S; Miyamoto M; Ariyoshi N; Kamataki T; Hémon D; Beaune P; Stücker I
Pharmacogenetics; 2001 Feb; 11(1):39-44. PubMed ID: 11207029
[TBL] [Abstract][Full Text] [Related]
2. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population.
Tan W; Chen GF; Xing DY; Song CY; Kadlubar FF; Lin DX
Int J Cancer; 2001 Mar; 95(2):96-101. PubMed ID: 11241319
[TBL] [Abstract][Full Text] [Related]
3. [Researches on the polymorphism of cytochrome P450 2A6].
Tong Z; ZhuGe J; Yu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Oct; 19(5):424-7. PubMed ID: 12362322
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers.
Ariyoshi N; Miyamoto M; Umetsu Y; Kunitoh H; Dosaka-Akita H; Sawamura Y; Yokota J; Nemoto N; Sato K; Kamataki T
Cancer Epidemiol Biomarkers Prev; 2002 Sep; 11(9):890-4. PubMed ID: 12223434
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.
Paschke T; Riefler M; Schuler-Metz A; Wolz L; Scherer G; McBride CM; Bepler G
Toxicology; 2001 Nov; 168(3):259-68. PubMed ID: 11684323
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.
Oscarson M; McLellan RA; Gullstén H; Agúndez JA; Benítez J; Rautio A; Raunio H; Pelkonen O; Ingelman-Sundberg M
FEBS Lett; 1999 Oct; 460(2):321-7. PubMed ID: 10544257
[TBL] [Abstract][Full Text] [Related]
7. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism.
Oscarson M
Drug Metab Dispos; 2001 Feb; 29(2):91-5. PubMed ID: 11159795
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
Fujieda M; Yamazaki H; Saito T; Kiyotani K; Gyamfi MA; Sakurai M; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Kamataki T
Carcinogenesis; 2004 Dec; 25(12):2451-8. PubMed ID: 15308589
[TBL] [Abstract][Full Text] [Related]
10. CYP2A6 polymorphism, nicotine, and environmental nitrosamines.
Idle JR
Lancet; 1999 Jun; 353(9169):2073. PubMed ID: 10376647
[No Abstract] [Full Text] [Related]
11. Determination of coumarin metabolism in Turkish population.
Cok I; Aygün Kocabaş N; Cholerton S; Karakaya AE; Sardaş S
Hum Exp Toxicol; 2001 Apr; 20(4):179-84. PubMed ID: 11393269
[TBL] [Abstract][Full Text] [Related]
12. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase.
Oscarson M; Gullstén H; Rautio A; Bernal ML; Sinues B; Dahl ML; Stengård JH; Pelkonen O; Raunio H; Ingelman-Sundberg M
FEBS Lett; 1998 Nov; 438(3):201-5. PubMed ID: 9827545
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of CYP2A6 in relation to cancer.
Kamataki T; Nunoya K; Sakai Y; Kushida H; Fujita K
Mutat Res; 1999 Jul; 428(1-2):125-30. PubMed ID: 10517986
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation of CYP2A6, smoking, and risk of cancer.
London SJ; Idle JR; Daly AK; Coetzee GA
Lancet; 1999 Mar; 353(9156):898-9. PubMed ID: 10093988
[No Abstract] [Full Text] [Related]
15. CYP2A6 gene deletion reduces susceptibility to lung cancer.
Miyamoto M; Umetsu Y; Dosaka-Akita H; Sawamura Y; Yokota J; Kunitoh H; Nemoto N; Sato K; Ariyoshi N; Kamataki T
Biochem Biophys Res Commun; 1999 Aug; 261(3):658-60. PubMed ID: 10441482
[TBL] [Abstract][Full Text] [Related]
16. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
[TBL] [Abstract][Full Text] [Related]
17. Association between CYP2A6 genetic polymorphisms and lung cancer: a meta-analysis of case-control studies.
Liu T; Xie CB; Ma WJ; Chen WQ
Environ Mol Mutagen; 2013 Mar; 54(2):133-40. PubMed ID: 23203414
[TBL] [Abstract][Full Text] [Related]
18. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of CYP2A6 and its practical consequences.
Raunio H; Rautio A; Gullstén H; Pelkonen O
Br J Clin Pharmacol; 2001 Oct; 52(4):357-63. PubMed ID: 11678779
[TBL] [Abstract][Full Text] [Related]
20. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.
Oscarson M; McLellan RA; Gullstén H; Yue QY; Lang MA; Bernal ML; Sinues B; Hirvonen A; Raunio H; Pelkonen O; Ingelman-Sundberg M
FEBS Lett; 1999 Apr; 448(1):105-10. PubMed ID: 10217419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
